Endometrial Stromal Sarcoma: An Update
Cancers · 05.06.2025 · 17 (11) · 1893
DOI: 10.3390/cancers17111893 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 05.06.2025. Verfasst von Giulio Ricotta und 8 weiteren Autor:innen. Beteiligte Einrichtung: Surgical Oncology, Oncopole Claudius Regaud-Institut Universitaire du Cancer Toulouse Oncopole, 31100 Toulouse, France. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Endometrial stromal sarcoma (ESS) is a rare malignant tumor of uterine mesenchyme, accounting for 15–20% of uterine sarcomas. It is classified into low-grade (LG-ESS) and high-grade (HG-ESS) subtypes, each defined by distinct histopathological and molecular features. LG-ESS exhibits slow progression, resembling proliferative-phase endometrial stroma, with genetic alterations like JAZF1-SUZ12 fusions. HG-ESS is more aggressive, characterized by high mitotic activity, necrosis, and genetic markers such as BCOR internal tandem duplication, often leading to advanced-stage diagnosis. Surgical resection is the cornerstone for managing early-stage ESS. A total hysterectomy with bilateral salpingo-oophorectomy (BSO) is recommended to prevent recurrence. Fertility-preserving approaches may be considered in LG-ESS but are associated with high recurrence rates. Lymphadenectomy is not routinely performed, given its limited prognostic value. HG-ESS, due to its aggressiveness, often requires additional treatment, including chemotherapy. Adjuvant therapy varies by subtype. LG-ESS responds well to hormonal treatments such as aromatase inhibitors and progestins, while tamoxifen is contraindicated. HG-ESS, lacking hormonal receptor expression, is managed with chemotherapy, often incorporating doxorubicin-based regimens. Radiotherapy may improve local control in select cases but shows limited impact on overall survival. Advanced-stage ESS treatment focuses on complete cytoreduction, supplemented by systemic therapies. Hormonal therapy remains the standard for advanced LG-ESS, whereas HG-ESS relies on chemotherapy. Prognosis depends on the subtype and stage. LG-ESS has favorable outcomes, with five-year survival exceeding 90% in early stages, but recurrent disease remains common. HG-ESS is associated with poorer survival due to its aggressive nature. Advances in molecular profiling offer promising avenues for personalized therapies, integrating genomic insights with targeted treatments to improve outcomes in this rare malignancy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Surgical Oncology, Oncopole Claudius Regaud-Institut Universitaire du Cancer Toulouse Oncopole, 31100 Toulouse, France.
- Gynecologic Oncology Unit, Department of Women, Child and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
- Oncology, Oncopole Claudius Regaud-Institut Universitaire du Cancer Toulouse Oncopole, 31100 Toulouse, France.
- Anatomopathology, Oncopole Claudius Regaud-Institut Universitaire du Cancer Toulouse Oncopole, 31100 Toulouse, France.
- INSERM CRCT19, Oncogenesis of Sarcomas, 31037 Toulouse, France.
ORCID-Profile: Giulio Ricotta, Silvio Andrea Russo, Valentin Thibaud, Bataillon Guillaume
Zitieren
APA
Ricotta, G., Russo, S. A., Fagotti, A., Martinez, A., Gauroy, E., Del, M., Thibaud, V., Guillaume, B., & Ferron, G. (2025). Endometrial Stromal Sarcoma: An Update. Cancers, 17(11), 1893. https://doi.org/10.3390/cancers17111893
Vancouver
Ricotta G, Russo SA, Fagotti A, Martinez A, Gauroy E, Del M, et al. Endometrial Stromal Sarcoma: An Update. Cancers. 2025;17(11):1893. doi:10.3390/cancers17111893
BibTeX
@article{Ricotta2025,
author = {Ricotta, Giulio and Russo, Silvio Andrea and Fagotti, Anna and Martinez, Alejandra and Gauroy, Elodie and Del, Mathilde and Thibaud, Valentin and Guillaume, Bataillon and Ferron, Gwenaël},
title = {Endometrial Stromal Sarcoma: An Update},
journal = {Cancers},
year = {2025},
volume = {17},
number = {11},
pages = {1893},
doi = {10.3390/cancers17111893}
}
EUVIMED